Afamelanotide

FDA-approved
Calculate Dose

For research use only.

Key Facts

CAS
75921-69-6
Molecular Weight (MW)
1646.9 g/mol
Half-life
~30 minutes (plasma); ~15 h (from implant)
Unit
mcg
Administration Route
Subcutaneous implant
Frequency
Every 2 months
Last updated
2/17/2026
Targets
MC1-R

Overview

—

Protocol

Dosage Range
16 mg implant
Frequency
Every 2 months
Cycle
Long-term use as prescribed
Administration Route
Subcutaneous implant
Reconstitution Guide
Subcutaneous implant - no reconstitution needed

Science

Mechanism of Action

Binds MC1-R, increases eumelanin production, provides photoprotection.

Targets

MC1-R

Studies

  • — Journal/year not available

Benefits

Increases pain-free sun exposure in EPPReduces phototoxic reactions

Potential Side Effects

  • Nausea
  • Headache
  • Implant site reactions

References

Related peptides

5-Amino-1MQ
Fat Loss
View details →
Abaloparatide
—
View details →
Acetyl Hexapeptide-8
—
View details →
Acetyl Octapeptide-3
—
View details →
Adamax
Cognitive
View details →
Angiotensin (1-7) Analog
—
View details →